PD-L1 and OX40 Binding Proteins for Cancer Regulation

Abstract: provided are monospecific and bispecific proteins that bind specifically to pd-l1. exemplary proteins release the inhibition through pd-l1. exemplary polyvalent proteins comprise at least one pd-l1 binding site. in certain embodiments, the binding sites may be linked through an immunoglobulin constant region. anti-pd-l1 antibodies are also provided. a pharmaceutical composition includes the antibody or the antigen-binding portion thereof as above mentioned and at least one pharmaceutically acceptable carrier.

Inventor(s): Jhong-Jhe YOU, Ching-Hsuan HSU, Po-Lin HUANG, Hung-Tsai KAN, Ting-Yi CHANG, Hsin-Ta HSIEH, Jeng-Horng HER

CPC Classification: C07K16/2878 (PEPTIDES (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))

Search for rejections for patent application number 20250154273